Supplementary Figure S20 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Ask about this paper

Answers are grounded in this paper and cite their sources.

Case studies of nodal immune flares after neoadjuvant durvalumab (A) and durvalumab+tremelimumab (B) therapy.

No takes yet. Share an insight, caveat, or question.

Kim et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark

Share